Case number 2018-1976
GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Feb 13, 2022 | 0 | GLAXOSMITHKLINE LLC v. TEVA PHARMACEUTICALS USA, INC. [ORDER] [precedential] (0) |
| Aug 8, 2021 | 0 | GLAXOSMITHKLINE LLC v. TEVA PHARMACEUTICALS USA, INC. [OPINION] [precedential] (0) |
| Apr 23, 2021 | 0 | GLAXOSMITHKLINE LLC v. TEVA PHARMACEUTICALS USA, INC. [OPINION] [precedential] (0) |
| Feb 18, 2021 | 185 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 02/18/2021 by email. [757214] [18-1976] [William Jay] [Entered: 02/18/2021 08:32 PM] (32) |
| Feb 12, 2021 | 183 | Response to notice of oral argument from Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Service: 02/12/2021 by email. [755846] [18-1976] [Juanita Brooks] [Entered: 02/12/2021 01:36 PM] (1) |
| Feb 12, 2021 | 184 | Response to notice of oral argument from Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 02/12/2021 by email. [755873] [18-1976] [William Jay] [Entered: 02/12/2021 02:20 PM] (1) |
| Feb 9, 2021 | 181 | ORDER filed. Teva Pharmaceuticals USA, Inc.'s petition [116] is granted to the extent that the 10/02/2020 judgment is vacated, the 10/02/2020 opinions are withdrawn, and the panel witll rehear these appeals on the merits. Telephonic oral argument is set for 02/23/2021 at 10:00 a.m. Oral argument shall be limited as noted in the order. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [754738] [18-1976, 18-2023] [MJL] [Entered: 02/09/2021 10:41 AM] (2) |
| Feb 9, 2021 | 182 | NOTICE OF TELEPHONIC ORAL ARGUMENT. Panel: 2102O. Case scheduled February 23, 2021. Response to Notice of Oral Argument due: 02/12/2021. The Clerk's Office will provide additional instructions to counsel at least one week ahead of argument. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [754747] [MJL] [Entered: 02/09/2021 10:48 AM] (1) |
| Feb 4, 2021 | 180 | RESPONSE of Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited to the supplemental authority [179]. Service: 02/04/2021 by email. [754074] [18-1976] [Juanita Brooks] [Entered: 02/04/2021 04:22 PM] (1) |
| Feb 2, 2021 | 179 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 02/02/2021 by email. [753531] [18-1976] [William Jay] [Entered: 02/02/2021 07:41 PM] (56) |
| Jan 29, 2021 | 177 | Amended Entry of appearance for Juanita R. Brooks; Michael A. Amon; Jonathan E. Singer as counsel for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Service: 01/29/2021 by email. [752887] [18-1976] [Michael Amon] [Entered: 01/29/2021 06:58 PM] (2) |
| Jan 29, 2021 | 178 | RESPONSE of Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited to the petition for en banc rehearing [116]. Service: 01/29/2021 by email. [752893] [18-1976] [Michael Amon] [Entered: 01/29/2021 07:48 PM] (24) |
| Jan 4, 2021 | 176 | 18 paper copies of Doc. No. [168] received from Amici Curiae Novartis Pharmaceuticals Corporation and Sandoz, Inc.. [748076] [VDW] [Entered: 01/08/2021 01:21 PM] (0) |
| Dec 30, 2020 | 167 | ORDER filed granting motion leave to file amicus brief on en banc or rehearing petition [132] filed by Novartis Pharmaceuticals Corporation and Sandoz Inc., granting motion leave to file amicus brief on en banc or rehearing petition [134] filed by Mylan Pharmaceuticals, Inc., granting motion leave to file amicus brief on en banc or rehearing petition [154] filed by Former Congressman Henry A. Waxman, granting motion leave to file amicus brief on en banc or rehearing petition [158] filed by Fifty-Seven Law, Economics, Business, Health, and Medicine Professors, granting motion leave to file amicus brief on en banc or rehearing petition [160] filed by Knowledge Ecology International and James Packard Love. By: Per Curiam. Service as of this date by the Clerk of Court. [745977] [JAB] [Entered: 12/30/2020 11:14 AM] (2) |
| Dec 30, 2020 | 168 | AMICUS BRIEF FILED on Petition by Novartis Pharmaceuticals Corporation and Sandoz, Inc. Service: 12/16/2020 by email. [745980] [JAB] [Entered: 12/30/2020 11:19 AM] (25) |
| Dec 30, 2020 | 169 | AMICUS BRIEF FILED on Petition by Mylan Pharmaceuticals Inc. Service: 12/16/2020 by email. [745981] [JAB] [Entered: 12/30/2020 11:22 AM] (19) |
| Dec 30, 2020 | 170 | CORRECTED AMICUS BRIEF FILED on Petition by Henry A. Waxman. Service: 12/18/2020 by email. [745982] [JAB] [Entered: 12/30/2020 11:25 AM] (20) |
| Dec 30, 2020 | 171 | CORRECTED AMICUS BRIEF FILED on Petition by Fifty-Seven Law, Economics, Business, Health, and Medicine Professors. Service: 12/22/2020 by email. [745986] [JAB] [Entered: 12/30/2020 11:30 AM] (34) |
| Dec 30, 2020 | 172 | CORRECTED AMICUS BRIEF FILED on Petition by Knowledge Ecology International and James Packard Love. Service: 12/28/2020 by email. [745987] [JAB] [Entered: 12/30/2020 11:32 AM] (18) |
| Dec 30, 2020 | 173 | Certificate of Interest for Amicus Curiae Sandoz, Inc.. Service: 12/30/2020 by email. [745988] [18-1976] [Dan Bagatell] [Entered: 12/30/2020 11:34 AM] (3) |
| Dec 30, 2020 | 174 | Certificate of Interest for Amicus Curiae Novartis Pharmaceuticals Corporation. Service: 12/30/2020 by email. [746008] [18-1976] [Jane Love] [Entered: 12/30/2020 12:21 PM] (3) |
| Dec 29, 2020 | 161 | ORDER filed granting motion leave to file amicus brief on en banc or rehearing petition [118] filed by Apotex Inc., granting motion leave to file amicus brief on en banc or rehearing petition [119] filed by The R Street Institute, granting motion leave to file amicus brief on en banc or rehearing petition [126] filed by Association for Accessible Medicines; granting motion to withdraw attorney [122] filed by Association for Accessible Medicines; granting motion leave to appear as counsel [156] filed by Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. By: Per Curiam. Service as of this date by the Clerk of Court. [745754] [JAB] [Entered: 12/29/2020 11:59 AM] (2) |
| Dec 29, 2020 | 162 | AMICUS BRIEF FILED on Petition by Apotex Inc. Service: 12/15/2020 by email. [745757] [JAB] [Entered: 12/29/2020 12:04 PM] (19) |
| Dec 29, 2020 | 163 | AMICUS BRIEF FILED on Petition by R Street Institute. Service: 12/15/2020 by email. [745758] [JAB] [Entered: 12/29/2020 12:06 PM] (18) |
| Dec 29, 2020 | 164 | AMICUS BRIEF FILED on Petition by Association for Accessible Medicines. Service: 12/16/2020 by email. [745760] [JAB] [Entered: 12/29/2020 12:09 PM] (22) |
| Dec 29, 2020 | 165 | Entry of appearance for Nitika Gupta Fiorella as counsel for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Service: 12/18/2020 by email. [745762] [JAB] [Entered: 12/29/2020 12:13 PM] (1) |
| Dec 29, 2020 | 166 | Certificate of Interest for Amicus Curiae Apotex Inc.. Service: 12/29/2020 by email. [745879] [18-1976] [Andrew Alul] [Entered: 12/29/2020 04:51 PM] (3) |
| Dec 28, 2020 | 160 | MOTION of Knowledge Ecology International and James Packard Love for leave to file amicus brief in support of Teva Pharmaceuticals, USA, Inc. on petition for en banc rehearing [116]. Service: 12/28/2020 by email. [745543] [18-1976] [Kathryn Ardizzone] [Entered: 12/28/2020 04:21 PM] (24) |
| Dec 23, 2020 | 159 | ORDER filed granting motion to extend time to file response to rehearing/en banc [150] filed by Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Response to Petition for Rehearing due on or before 01/29/2021. By: Per Curiam. Service as of this date by the Clerk of Court. [745152] [JAB] [Entered: 12/23/2020 03:25 PM] (2) |
| Dec 22, 2020 | 157 | Corrected Entry of appearance for Michael A. Carrier; Matthew J. Dowd; Robert J. Scheffel as counsel for Amicus Curiae Fifty-Seven Law, Economics, Business, Health, and Medicine Professors. Service: 12/22/2020 by email. [744843] [18-1976] [Michael Carrier] [Entered: 12/22/2020 03:55 PM] (7) |
| Dec 22, 2020 | 158 | MOTION of Amici Curiae Fifty-Seven Law, Economics, Business, Health, and Medicine Professors for leave to file amicus brief in support of Cross-Appellant Teva Pharmaceuticals USA, Inc. on petition [116]. Service: 12/22/2020 by email. [744860] [18-1976] [Michael Carrier] [Entered: 12/22/2020 04:21 PM] (47) |
| Dec 18, 2020 | 151 | NOTICE OF NON-COMPLIANCE: The submission of GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited, Entry of Appearance [148], is not in compliance with the rules of this court (see attached). Compliant document due 12/29/2020. Service as of this date by the Clerk of Court. [743645] [MJL] [Entered: 12/18/2020 08:24 AM] (1) |
| Dec 18, 2020 | 152 | Corrected Entry of appearance for Steffen N. Johnson; Tung-On Kong; Wendy L. Devine; Adam W. Burrowbridge; John B. Kenney; G. Edward Powell III as counsel for Mylan Pharmaceuticals Inc.. Service: 12/18/2020 by email. [743796] [18-1976] [Steffen Johnson] [Entered: 12/18/2020 12:50 PM] (2) |
| Dec 18, 2020 | 153 | Corrected Entry of appearance for William B. Schultz; Margaret M. Dotzel; Cassandra Trombley-Shapiro Jonas as counsel for Former Congressman Henry A. Waxman. Service: 12/18/2020 by email. [743805] [18-1976] [Cassandra Jonas] [Entered: 12/18/2020 01:13 PM] (2) |
| Dec 18, 2020 | 154 | MOTION of Former Congressman Henry A. Waxman for leave to file amicus brief in support of Teva Pharmaceuticals USA, Inc. on petition for en banc rehearing [116]. Service: 12/18/2020 by email. [743811] [18-1976] [Cassandra Jonas] [Entered: 12/18/2020 01:19 PM] (26) |
| Dec 18, 2020 | 155 | Corrected Certificate of Interest for Former Congressman Henry A. Waxman. Service: 12/18/2020 by email. [743817] [18-1976] [Cassandra Jonas] [Entered: 12/18/2020 01:20 PM] (3) |
| Dec 18, 2020 | 156 | MOTION of Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited for leave to file entry of appearance(s) for Nitika Gupta Fiorella. Service: 12/18/2020 by email. [744023] [18-1976] [Michael Amon] [Entered: 12/18/2020 05:08 PM] (7) |
| Dec 18, 2020 | 175 | 18 paper copies of Doc. No. [169] received from Mylan Pharmaceuticals Inc. [746035] [MJL] [Entered: 12/30/2020 02:05 PM] (0) |
| Dec 17, 2020 | 142 | NOTICE OF NON-COMPLIANCE: The submissions by Fifty-Seven Professors (entry of appearance [127], motion [128], brief [129]) are not in compliance with the rules of this court (see attached). Compliant documents due 12/28/2020. Unless ordered otherwise, the deadline for any responsive filing runs from service of the original version. Service as of this date by the Clerk of Court. [743466] [MJL] [Entered: 12/17/2020 11:39 AM] (2) |
| Dec 17, 2020 | 143 | NOTICE OF NON-COMPLIANCE: The submission of Novartis Pharmaceuticals Corporation, Entry of Appearance [131], is not in compliance with the rules of this court (see attached). Compliant document due 12/28/2020. Service as of this date by the Clerk of Court. [743476] [MJL] [Entered: 12/17/2020 11:56 AM] (1) |
| Dec 17, 2020 | 144 | NOTICE OF NON-COMPLIANCE: The submission of Mylan Pharmaceuticals Inc., Entry of Appearance [133], is not in compliance with the rules of this court (see attached). Compliant document due 12/28/2020. Service as of this date by the Clerk of Court. [743477] [MJL] [Entered: 12/17/2020 12:05 PM] (1) |
| Dec 17, 2020 | 145 | NOTICE OF NON-COMPLIANCE: The submissions of Henry A. Waxman and Waxman Consulting, Inc. (entry of appearance [135], motion [136], brief [137], certificate of interest [138]) are not in compliance with the rules of this court (see attached). Compliant documents due 12/28/2020. Unless ordered otherwise, the deadline for any responsive filing runs from service of the original version. Service as of this date by the Clerk of Court. [743479] [MJL] [Entered: 12/17/2020 12:20 PM] (3) |
| Dec 17, 2020 | 146 | NOTICE OF NON-COMPLIANCE: The submissions of Knowledge Ecology International and James Packard Love, motion [140] and brief [141], are not in compliance with the rules of this court (see attached). Compliant documents due 12/28/2020. Unless ordered otherwise, the deadline for any responsive filing runs from service of the original version. Service as of this date by the Clerk of Court. [743489] [MJL] [Entered: 12/17/2020 01:11 PM] (2) |
| Dec 17, 2020 | 147 | Corrected Entry of appearance for Jane M. Love, Ph.D.; Robert W. Trenchard as counsel for Novartis Pharmaceuticals Corporation. Service: 12/17/2020 by email. [743577] [18-1976] [Jane Love] [Entered: 12/17/2020 04:36 PM] (1) |
| Dec 17, 2020 | 148 | Entry of appearance for Nitika Gupta Fiorella as counsel for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Service: 12/17/2020 by email. [743622] [18-1976]. This document is non-compliant. See Doc. No. [151]. [Nitika Gupta Fiorella] [Entered: 12/17/2020 07:21 PM] (1) |
| Dec 17, 2020 | 149 | Amended Certificate of Interest for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Service: 12/17/2020 by email. [743633] [18-1976] [Michael Amon] [Entered: 12/17/2020 08:48 PM] (3) |
| Dec 17, 2020 | 150 | MOTION of Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited to extend the time to file a response to the Petition for Rehearing En Banc until 01/29/2021. Service: 12/17/2020 by email. [743635] [18-1976] [Michael Amon] [Entered: 12/17/2020 08:55 PM] (11) |
| Dec 16, 2020 | 122 | MOTION of Amicus Curiae Association for Accessible Medicines to withdraw counsel Andrew C. Nichols. Service: 12/16/2020 by email. [743164] [18-1976] [Andrew Nichols] [Entered: 12/16/2020 11:56 AM] (4) |
| Dec 16, 2020 | 123 | Notice from Amicus Curiae Association for Accessible Medicines of Withdrawal of Counsel. Service: 12/16/2020 by email. [743185] [18-1976] [Kurt Mathas] [Entered: 12/16/2020 12:47 PM] (3) |
| Dec 16, 2020 | 124 | The court invites a response from Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited to the petition for en banc rehearing filed by Cross-Appellant in 18-1976. Response due on 12/30/2020. Service as of this date by the Clerk of Court. [743198] [JAB] [Entered: 12/16/2020 01:08 PM] (1) |
| Dec 16, 2020 | 125 | Entry of appearance for Matthew S. Hellman; Noah B. Bokat-Lindell as counsel for Amicus Curiae Association for Accessible Medicines. Service: 12/16/2020 by email. [743280] [18-1976] [Matthew Hellman] [Entered: 12/16/2020 04:10 PM] (1) |
| Dec 16, 2020 | 126 | MOTION of Amicus Curiae Association for Accessible Medicines for leave to file amicus brief in support of Defendant-Cross-Appellant Teva Pharmaceuticals USA, Inc. on petition [116]. Service: 12/16/2020 by email. [743308] [18-1976] [Matthew Hellman] [Entered: 12/16/2020 04:39 PM] (31) |
| Dec 16, 2020 | 127 | Entry of appearance for Michael A. Carrier; Matthew J. Dowd; Robert J. Scheffel as counsel for Fifty-Seven Law, Economics, Business, Health, and Medicine Professors. Service: 12/16/2020 by email. [743326] [18-1976]. This document is non-compliant. See Doc. No. [142]. [Matthew Dowd] [Entered: 12/16/2020 05:18 PM] (2) |
| Dec 16, 2020 | 128 | MOTION of Fifty-Seven Law, Economics, Business, Health, and Medicine Professors for leave to file amicus brief in support of In support of Cross-Appellant Teva Pharmaceuticals USA, Inc. on petition [116]. Service: 12/16/2020 by email. [743327] [18-1976]. This document is non-compliant. See Doc. No. [142]. [Matthew Dowd] [Entered: 12/16/2020 05:21 PM] (13) |
| Dec 16, 2020 | 129 | AMICUS CURIAE BRIEF FILED by Fifty-Seven Law, Economics, Business, Health, and Medicine Professors. Service: 12/16/2020 by email. [743330] [18-1976]. This document is non-compliant. See Doc. No. [142]. [Matthew Dowd] [Entered: 12/16/2020 05:24 PM] (34) |
| Dec 16, 2020 | 130 | Entry of appearance for Dan L. Bagatell; Andrew T. Dufresne as counsel for Sandoz Inc.. Service: 12/16/2020 by email. [743345] [18-1976] [Dan Bagatell] [Entered: 12/16/2020 06:06 PM] (1) |
| Dec 16, 2020 | 131 | Entry of appearance for Jane M. Love, Ph.D; Robert W. Trenchard as counsel for Novartis Pharmaceuticals Corporation. Service: 12/16/2020 by email. [743347] [18-1976]. This document is non-compliant. See Doc. No. [143]. [Dan Bagatell] [Entered: 12/16/2020 06:08 PM] (1) |
| Dec 16, 2020 | 132 | MOTION of Novartis Pharmaceuticals Corporation and Sandoz Inc. for leave to file amicus brief in support of rehearing en banc but neither party on petition [116]. Service: 12/16/2020 by email. [743349] [18-1976] [Dan Bagatell] [Entered: 12/16/2020 06:23 PM] (37) |
| Dec 16, 2020 | 133 | Entry of appearance for Steffen N. Johnson; Tung-On Kong; Wendy L. Devine; Adam W. Burrowbridge; John B. Kenney; G. Edward Powell III as counsel for Mylan Pharmaceuticals, Inc.. Service: 12/16/2020 by email. [743350] [18-1976]. This document is non-compliant. See Doc. No. [144]. [Steffen Johnson] [Entered: 12/16/2020 06:28 PM] (2) |
| Dec 16, 2020 | 134 | MOTION of Mylan Pharmaceuticals, Inc. for leave to file amicus brief in support of Defendant-Cross-Appellant Teva Pharmaceuticals USA, Inc. on petition [116]. Service: 12/16/2020 by email. [743353] [18-1976] [Steffen Johnson] [Entered: 12/16/2020 06:42 PM] (25) |
| Dec 16, 2020 | 135 | Entry of appearance for William B. Schultz; Margaret Dotzel; Casey Trombley-Shapiro Jonas as counsel for Former Congressman Henry A. Waxman; Waxman Consulting, Inc.. Service: 12/16/2020 by email. [743354] [18-1976]. This document is non-compliant. See Doc. No. [145]. [William Schultz] [Entered: 12/16/2020 07:21 PM] (2) |
| Dec 16, 2020 | 136 | MOTION of Former Congressman Henry A. Waxman for leave to file amicus brief in support of Teva Pharmaceuticals USA, Inc. on petition for en banc rehearing [116]. Service: 12/16/2020 by email. [743355] [18-1976]. This document is non-compliant. See Doc. No. [145]. [William Schultz] [Entered: 12/16/2020 07:25 PM] (5) |
| Dec 16, 2020 | 137 | AMICUS CURIAE BRIEF FILED by Former Congressman Henry A. Waxman. Service: 12/16/2020 by email. [743356] [18-1976]. This document is non-compliant. See Doc. No. [145]. [William Schultz] [Entered: 12/16/2020 07:29 PM] (20) |
| Dec 16, 2020 | 138 | Certificate of Interest for Former Congressman Henry A. Waxman. Service: 12/16/2020 by email. [743357] [18-1976]. This document is non-compliant. See Doc. No. [145]. [William Schultz] [Entered: 12/16/2020 07:31 PM] (3) |
| Dec 16, 2020 | 139 | MODIFIED ENTRY: Entry of appearance for Kathryn Ardizzone as counsel for Knowledge Ecology International and James Packard Love. Service: 12/16/2020 by email. [743363]--[Edited 12/17/2020 by MJL to correct filing event] [Kathryn Ardizzone] [Entered: 12/16/2020 11:54 PM] (2) |
| Dec 16, 2020 | 140 | MOTION of Knowledge Ecology International and James Packard Love for leave to file an amicus curiae brief. Service: 12/16/2020 by email. [743364] [18-1976]. This document is non-compliant. See Doc. No. [146]. [Kathryn Ardizzone] [Entered: 12/16/2020 11:55 PM] (5) |
| Dec 16, 2020 | 141 | Notice from Knowledge Ecology International and James Packard Love Attached Amici Curiae Brief. Service: 12/16/2020 by email. [743365] [18-1976]. This document is non-compliant. See Doc. No. [146]. [Kathryn Ardizzone] [Entered: 12/16/2020 11:57 PM] (20) |
| Dec 15, 2020 | 117 | Entry of appearance for Andrew M. Alul as counsel for Apotex Inc.. Service: 12/15/2020 by email. [742860] [18-1976] [Andrew Alul] [Entered: 12/15/2020 02:07 PM] (1) |
| Dec 15, 2020 | 118 | MOTION of Apotex Inc. for leave to file amicus brief in support of Defendant - Cross-Appellant Teva Pharmaceuticals USA, Inc. on petition for en banc rehearing [116]. Service: 12/15/2020 by email. [742868] [18-1976] [Andrew Alul] [Entered: 12/15/2020 02:18 PM] (28) |
| Dec 15, 2020 | 119 | MOTION of The R Street Institute for leave to file amicus brief in support of Defendant-Cross-Appellant Teva Pharmaceuticals USA, Inc. on petition for en banc rehearing [116]. Service: 12/15/2020 by email. [743017] [18-1976] [Mason Kortz] [Entered: 12/15/2020 08:57 PM] (23) |
| Dec 15, 2020 | 120 | Entry of appearance for Mason A. Kortz as counsel for The R Street Institute. Service: 12/15/2020 by email. [743018] [18-1976] [Mason Kortz] [Entered: 12/15/2020 09:01 PM] (1) |
| Dec 15, 2020 | 121 | Certificate of Interest for The R Street Institute. Service: 12/15/2020 by email. [743019] [18-1976] [Mason Kortz] [Entered: 12/15/2020 09:03 PM] (1) |
| Dec 2, 2020 | 116 | Petition for en banc rehearing filed by Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 12/02/2020 by email. [739781] [18-1976] [William Jay] [Entered: 12/02/2020 05:08 PM] (85) |
| Oct 21, 2020 | 115 | Notice from Amicus Curiae Pharmaceutical Research and Manufacturers of America Notice of Withdrawal of Counsel. Service: 10/21/2020 by email. [730709] [18-1976] [Steven Winkelman] [Entered: 10/21/2020 05:27 PM] (3) |
| Oct 16, 2020 | 114 | ORDER filed granting Teva Pharmaceuticals USA, Inc.'s [113] motion to extend the time to file a petition for rehearing by 30 days, until 12/02/2020. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [729399] [MJL] [Entered: 10/16/2020 01:29 PM] (2) |
| Oct 14, 2020 | 113 | MOTION of Cross-Appellant Teva Pharmaceuticals USA, Inc. to extend the time to file a Combined Petition for Panel Rehearing and Rehearing En Banc until 12/02/2020. Service: 10/14/2020 by email. [728726] [18-1976] [William Jay] [Entered: 10/14/2020 05:13 PM] (9) |
| Oct 2, 2020 | 111 | OPINION filed for the court by Prost, Chief Judge; Newman, Circuit Judge and Moore, Circuit Judge. Dissenting opinion filed by Chief Judge Prost. Precedential Opinion. [726095] [18-1976, 18-2023]. Withdrawn pursuant to the court's order. See Doc. No. [181]. [MJL] [Entered: 10/02/2020 11:01 AM] (53) |
| Oct 2, 2020 | 112 | JUDGMENT. VACATED AND REMANDED. Terminated on the merits after oral argument. COSTS: Each side bears its own costs. Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [726098] [18-1976, 18-2023]. Vacated pursuant to the court's order. See Doc. No. [181]. [MJL] [Entered: 10/02/2020 11:11 AM] (1) |
| Dec 30, 2019 | 110 | Amended Entry of appearance for Jaime A. Santos as of counsel for Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 12/30/2019 by email. [659608] [18-1976] [Jaime Santos] [Entered: 12/30/2019 05:41 PM] (2) |
| Nov 8, 2019 | 109 | Amended Entry of appearance for William M. Jay as principal counsel for Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 11/08/2019 by email. [648200] [18-1976] [William Jay] [Entered: 11/08/2019 02:14 PM] (2) |
| Sep 6, 2019 | 107 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 09/06/2019 by email. [633534] [18-1976] [William Jay] [Entered: 09/06/2019 08:55 AM] (4) |
| Sep 6, 2019 | 108 | RESPONSE of Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited to the supplemental authority [107] filed by Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 09/06/2019 by email. [633729] [18-1976] [Juanita Brooks] [Entered: 09/06/2019 03:03 PM] (3) |
| Sep 4, 2019 | 106 | Submitted after ORAL ARGUMENT by Ms. Juanita Rose Brooks for GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited and Mr. William M. Jay for Teva Pharmaceuticals USA, Inc. Panel: Judge: Prost , Judge: Newman , Judge: Moore. [632993] [JCP] [Entered: 09/04/2019 11:15 AM] (0) |
| Jul 26, 2019 | 105 | Response to notice of oral argument from the Cross-Appellant Teva Pharmaceuticals USA, Inc.. [623853] [18-1976] [William Jay] [Entered: 07/26/2019 04:18 PM] (3) |
| Jul 25, 2019 | 104 | Response to notice of oral argument from the Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. [623645] [18-1976] [Juanita Brooks] [Entered: 07/25/2019 07:17 PM] (3) |
| Jul 22, 2019 | 103 | NOTICE OF ORAL ARGUMENT. Panel: 1909E. Case scheduled September 04, 2019 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 402. Response to Notice of Oral Argument due: 08/15/2019. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [622510] [JAB] [Entered: 07/22/2019 12:56 PM] (2) |
| Jun 13, 2019 | 102 | The following conflict dates submitted by Attorney Juanita Rose Brooks for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited have been accepted by the court: 08/08/2019, 08/09/2019. [613731] [JAB] [Entered: 06/13/2019 08:02 AM] (0) |
| Jun 12, 2019 | 101 | Notice from Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited regarding conflicts with oral argument. Service: 06/12/2019 by email. [613628] [18-1976] [Juanita Brooks] [Entered: 06/12/2019 03:53 PM] (4) |
| May 16, 2019 | 100 | MODIFIED ENTRY: The following conflict dates submitted by Attorney Juanita Rose Brooks for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited have been accepted by the court: 07/11/2019, 07/12/2019, 11/08/2019. [607802]--[Edited 05/16/2019 by JAB to correct conflict dates] [JAB] [Entered: 05/16/2019 08:38 AM] (0) |
| May 15, 2019 | 98 | Notice from Appellant GlaxoSmithKline LLC regarding conflicts with oral argument. Service: 05/15/2019 by email. [607744] [18-1976] [Juanita Brooks] [Entered: 05/15/2019 06:48 PM] (3) |
| May 15, 2019 | 99 | Notice from Appellant GlaxoSmithKline LLC regarding conflicts with oral argument. Service: 05/15/2019 by email. [607757] [18-1976] [Juanita Brooks] [Entered: 05/15/2019 07:40 PM] (4) |
| Apr 12, 2019 | 94 | 6 paper copies of the Corrected Reply Brief [78] received from Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. [599590] [CJF] [Entered: 04/12/2019 09:53 AM] (0) |
| Apr 12, 2019 | 95 | 6 paper copies of the Corrected Confidential Joint Appendix Brief (Vol. I - II) [87] received from Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. [599594] [CJF] [Entered: 04/12/2019 10:00 AM] (0) |
| Apr 12, 2019 | 96 | Notice from Cross-Appellant Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument. Service: 04/12/2019 by email. [599597] [18-1976] [William Jay] [Entered: 04/12/2019 10:09 AM] (3) |
| Apr 12, 2019 | 97 | The following conflict dates submitted by Attorney William M. Jay for Cross-Appellant Teva Pharmaceuticals USA, Inc. have been accepted by the court: 06/06/2019, 07/12/2019, 08/09/2019, 09/03/2019, 09/30/2019, 10/01/2019. [599678] [JAB] [Entered: 04/12/2019 01:05 PM] (0) |
| Apr 10, 2019 | 93 | The following conflict dates submitted by Attorney Juanita Rose Brooks for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited have been accepted by the court: 06/03/2019, 06/04/2019, 06/05/2019, 06/06/2019, 06/07/2019. [598846] [JAB] [Entered: 04/10/2019 08:01 AM] (0) |
| Apr 9, 2019 | 91 | 6 paper copies of the Reply Brief [76] received from Cross-Appellant Teva Pharmaceuticals USA, Inc.. [598765] [CJF] [Entered: 04/09/2019 02:53 PM] (0) |
| Apr 9, 2019 | 92 | Notice from Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited regarding conflicts with oral argument. Service: 04/09/2019 by email. [598827] [18-1976] [Juanita Brooks] [Entered: 04/09/2019 05:26 PM] (3) |
| Apr 5, 2019 | 89 | Outstanding paper copies of all briefs and appendices must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(1). [598154] [TAM] [Entered: 04/05/2019 03:15 PM] (0) |
| Apr 5, 2019 | 90 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The notice of conflict with oral argument is due on or before 04/12/2019. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [598155] [TAM] [Entered: 04/05/2019 03:16 PM] (1) |
| Mar 27, 2019 | 87 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL JOINT APPENDIX FILED for GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Number of Pages: 1093. Service: 03/27/2019 by email. [596026]--[Edited 04/05/2019 by TAM - compliance review complete] [Michael Amon] [Entered: 03/27/2019 07:37 PM] (0) |
| Mar 27, 2019 | 88 | MODIFIED ENTRY: CORRECTED JOINT APPENDIX FILED for GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Number of Pages: 1095. Service: 03/27/2019 by email. [596027] --[Edited 04/05/2019 by TAM - compliance review complete] [Michael Amon] [Entered: 03/27/2019 07:41 PM] (1095) |
| Mar 20, 2019 | 86 | NOTICE OF NON-COMPLIANCE: The submission of Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited, Confidential Joint Appendix and Non-Confidential Joint Appendix [84], [83], are not in compliance with the rules of this court (see attached). Compliant document due on 03/27/2019. Service as of this date by the Clerk of Court.[594238]--[Edited 03/21/2019 by TAM to revise reasons for non-compliance listed in attached document] [TAM] [Entered: 03/20/2019 02:09 PM] (2) |
| Mar 14, 2019 | 85 | 6 paper copies of the Corrected Response Brief [80] received from Cross-Appellant Teva Pharmaceuticals USA, Inc.. [592842] [CJF] [Entered: 03/14/2019 12:31 PM] (0) |
| Mar 12, 2019 | 81 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 03/12/2019 by email. [592239] [18-1976] [William Jay] [Entered: 03/12/2019 02:49 PM] (3) |
| Mar 12, 2019 | 82 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellants GlaxoSmithKline LLC, SmithKline Beecham (Cork) Limited and Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 03/12/2019 by email. [592354] [18-1976] [Michael Amon] [Entered: 03/12/2019 05:43 PM] (3) |
| Mar 12, 2019 | 83 | FILED from Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Title: CONFIDENTIAL JOINT APPENDIX. Service: 03/12/2019 by email. [592382] [18-1976] This document is non-compliant. See Doc No. [86] [Michael Amon] [Entered: 03/12/2019 08:08 PM] (0) |
| Mar 12, 2019 | 84 | FILED from Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Title: JOINT APPENDIX. Service: 03/12/2019 by email. [592383] [18-1976] This document is non-compliant. See Doc No. [86] [Michael Amon] [Entered: 03/12/2019 08:17 PM] (1091) |
| Mar 11, 2019 | 79 | Notice of Correction to the Opening Response Brief Doc No. [56] for Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 03/11/2019 by email. [591993] [18-1976] [William Jay] [Entered: 03/11/2019 04:40 PM] (3) |
| Mar 11, 2019 | 80 | MODIFIED ENTRY: CORRECTED RESPONSE BRIEF FILED for Cross-Appellant Teva Pharmaceuticals USA, Inc.. Number of Pages: 74. Service: 03/11/2019 by email. [591995]--[Edited 03/20/2019 by TAM - compliance review complete] [William Jay] [Entered: 03/11/2019 04:43 PM] (89) |
| Mar 5, 2019 | 76 | MODIFIED ENTRY: REPLY BRIEF FILED for Cross-Appellant Teva Pharmaceuticals USA, Inc. Number of Pages: 25. Service: 03/05/2019 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [590564] --[Edited 03/20/2019 by TAM - compliance review complete] [William Jay] [Entered: 03/05/2019 06:20 PM] (34) |
| Mar 5, 2019 | 77 | Notice of Correction to the Brief Doc No. [73], Reply Brief Doc No. [73] for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Service: 03/05/2019 by email. [590569] [18-1976] [Michael Amon] [Entered: 03/05/2019 08:20 PM] (3) |
| Mar 5, 2019 | 78 | MODIFIED ENTRY: CORRECTED REPLY BRIEF FILED for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Number of Pages: 37. Service: 03/05/2019 by email. [590570]--[Edited 03/20/2019 by TAM - compliance review complete] [Michael Amon] [Entered: 03/05/2019 08:25 PM] (45) |
| Feb 12, 2019 | 75 | **TEXT ONLY** ORDER granting motion to extend time to file Cross-Appellant's Reply Brief [74] filed by Cross-Appellant Teva Pharmaceuticals USA, Inc. Cross-Appellant's reply brief due 03/05/2019. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [585198] [TAM] [Entered: 02/12/2019 12:34 PM] (0) |
| Feb 7, 2019 | 74 | MOTION of Cross-Appellant Teva Pharmaceuticals USA, Inc. to extend the time to 03/05/2019 to file the Cross-Appeal Reply Brief. [Consent: unopposed]. Service: 02/07/2019 by email. [584065] [18-1976] [William Jay] [Entered: 02/07/2019 12:08 PM] (6) |
| Jan 29, 2019 | 73 | MODIFIED ENTRY: REPLY BRIEF FILED for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Number of Pages: 37. Service: 01/29/2019 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [581933] --[Edited 02/12/2019 by TAM - compliance review complete] This brief has been corrected. See Doc No. [78] [Craig Countryman] [Entered: 01/29/2019 07:09 PM] (45) |
| Dec 20, 2018 | 72 | ORDER filed. The stay of the briefing schedule is lifted. The motion [57] is denied, without prejudice to GSK’s right to address the propriety of Teva’s cross appeal in its merits briefing. See Fed. Cir. R. 27(f). GSK’s response and reply brief is due within 40 days of the date of filing of this order. Service: 12/20/2018 by clerk. [573362] [NL] [Entered: 12/20/2018 09:08 AM] (2) |
| Nov 28, 2018 | 70 | ORDER granting motion to withdraw Andrew E. Riley as counsel [67] filed by Cross-Appellant Teva Pharmaceuticals USA, Inc. Service as of this date by the Clerk of Court. [568161] [CAB] [Entered: 11/28/2018 10:57 AM] (2) |
| Nov 28, 2018 | 71 | 6 paper copies of the Corrected Amicus Brief [69] received from Amicus Curiae Association for Accessible Medicines. [569817] [CJF] [Entered: 12/06/2018 10:33 AM] (0) |
| Nov 26, 2018 | 68 | REPLY of Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited to response filed by Cross-Appellant, Doc. No [65]. Service: 11/26/2018 by email. [567598] [18-1976] [Craig Countryman] [Entered: 11/26/2018 05:45 PM] (10) |
| Nov 21, 2018 | 67 | MOTION of Cross-Appellant Teva Pharmaceuticals USA, Inc. to withdraw counsel Andrew E. Riley [Consent: unopposed]. Service: 11/21/2018 by email. [567056] [18-1976] [William Jay] [Entered: 11/21/2018 10:11 AM] (4) |
| Nov 20, 2018 | 66 | ORDER filed. The briefing schedule is stayed pending further order of the court. Service: 11/20/2018 by clerk. [566620] [LMS] [Entered: 11/20/2018 10:08 AM] (2) |
| Nov 19, 2018 | 65 | RESPONSE of Cross-Appellant Teva Pharmaceuticals USA, Inc. to the motion to terminate appeal [57] filed by Appellants GlaxoSmithKline LLC, SmithKline Beecham (Cork) Limited, GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Service: 11/19/2018 by email. [566457] [18-1976] [William Jay] [Entered: 11/19/2018 04:41 PM] (11) |
| Nov 14, 2018 | 60 | 6 paper copies of the Corrected Opening Response Brief [56] received from Cross-Appellant Teva Pharmaceuticals USA, Inc.. [564794] [CJF] [Entered: 11/14/2018 11:45 AM] (0) |
| Nov 14, 2018 | 61 | Entry of appearance for Jeffrey K. Francer as of counsel for Amicus Curiae Association for Accessible Medicines. Service: 11/14/2018 by email. [564999] [18-1976] [Andrew Nichols] [Entered: 11/14/2018 05:51 PM] (2) |
| Nov 14, 2018 | 62 | Entry of appearance for George C. Lombardi as of counsel for Amicus Curiae Association for Accessible Medicines. Service: 11/14/2018 by email. [565001] [18-1976] [George Lombardi] [Entered: 11/14/2018 05:54 PM] (2) |
| Nov 14, 2018 | 63 | Entry of appearance for Kurt A. Mathas as of counsel for Amicus Curiae Association for Accessible Medicines. Service: 11/14/2018 by email. [565002] [18-1976] [Kurt Mathas] [Entered: 11/14/2018 05:56 PM] (2) |
| Nov 14, 2018 | 64 | TENDERED from Amicus Curiae Association for Accessible Medicines. Title: CORRECTED AMICUS CURIAE BRIEF. Service: 11/14/2018 by email. [565005] [18-1976] [Andrew Nichols] [Entered: 11/14/2018 05:59 PM] (40) |
| Nov 14, 2018 | 69 | CORRECTED AMICUS BRIEF FILED for Association for Accessible Medicines [64]. Number of Pages: 31. Service: 11/14/2018 by email. [567691] [JB] [Entered: 11/27/2018 08:58 AM] (40) |
| Nov 13, 2018 | 59 | NOTICE OF NON-COMPLIANCE: The submission of Amicus Curiae Association for Accessible Medicines, Amicus Curiae Brief [55], is not in compliance with the rules of this court (see attached). Amicus brief due 11/20/2018. Service as of this date by the Clerk of Court.[564278] [JB] [Entered: 11/13/2018 10:49 AM] (2) |
| Nov 9, 2018 | 58 | 6 paper copies of the Opening Principal and Response Brief [56] received from Cross-Appellant Teva Pharmaceuticals USA, Inc.. [563933] [CJF] [Entered: 11/09/2018 01:29 PM] (0) |
| Nov 7, 2018 | 57 | CORRECTED ENTRY: MOTION of Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited to terminate appeal through dismissal. Cases to be terminated: 18-2023 [Consent: opposed]. Service: 11/07/2018 by email. [563429]--[Edited 11/08/2018 by MJL to correct relief] [Craig Countryman] [Entered: 11/07/2018 05:54 PM] (38) |
| Nov 2, 2018 | 54 | Entry of appearance for Andrew C. Nichols as principal counsel for Association for Accessible Medicines. Service: 11/02/2018 by email. [562384] [18-1976] [Andrew Nichols] [Entered: 11/02/2018 04:54 PM] (2) |
| Nov 2, 2018 | 55 | TENDERED from Association for Accessible Medicines Title: AMICUS CURIAE BRIEF. Service: 11/02/2018 by email. [562389] [18-1976] This document is non-compliant. See Doc No.[59] [Andrew Nichols] [Entered: 11/02/2018 05:12 PM] (0) |
| Oct 26, 2018 | 53 | TENDERED from Cross-Appellant Teva Pharmaceuticals USA, Inc.. Title: RESPONSE BRIEF. Service: 10/26/2018 by email. [560773] [18-1976] [William Jay] [Entered: 10/26/2018 08:43 PM] (89) |
| Oct 26, 2018 | 56 | BRIEF FILED for Cross-Appellant Teva Pharmaceuticals USA, Inc. [53]. Number of Pages: 74. Service: 10/26/2018 by email. The paper copies of the brief should be received by the court on or before 11/15/2018. Appellant's reply brief is due 12/05/2018. [563259] This brief has been corrected. See Doc No. [80] [JB] [Entered: 11/07/2018 01:21 PM] (89) |
| Aug 10, 2018 | 50 | NOTICE OF NON-COMPLIANCE: The submission of Cross-Appellant Teva Pharmaceuticals USA, Inc., Entry of appearance for Jaime Santos [48], is not in compliance with the rules of this court (see attached). Compliant document due on 08/17/2018. Service as of this date by the Clerk of Court. [541930] [SJL] [Entered: 08/10/2018 08:58 AM] (1) |
| Aug 10, 2018 | 51 | **TEXT ONLY** ORDER granting motion to extend time to file brief [49] filed by Cross-Appellant Teva Pharmaceuticals USA, Inc. Cross-Appellant Teva Pharmaceuticals USA, Inc. brief due 10/26/2018. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [542059] [SJ] [Entered: 08/10/2018 12:01 PM] (0) |
| Aug 10, 2018 | 52 | Corrected Entry of appearance for Jaime A. Santos as of counsel for Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 08/10/2018 by email. [542090] [18-1976] [Jaime Santos] [Entered: 08/10/2018 01:21 PM] (2) |
| Aug 9, 2018 | 48 | Entry of appearance for Jaime A. Santos as of counsel for Cross-Appellant Teva Pharmaceuticals USA, Inc. Service: 08/09/2018 by email. [541892] [18-1976] This document is non-complaint. See Doc. No [50] [Jaime Santos] [Entered: 08/09/2018 05:03 PM] (2) |
| Aug 9, 2018 | 49 | MOTION of Cross-Appellant Teva Pharmaceuticals USA, Inc. to extend the time to 10/26/2018 to file the Principal and Response Brief (a 60-day extension of the deadline from August 27, 2018, to October 26, 2018). [Consent: unopposed]. Service: 08/09/2018 by email. [541893] [18-1976] [William Jay] [Entered: 08/09/2018 05:16 PM] (8) |
| Aug 3, 2018 | 47 | 6 paper copies of the Corrected Amicus Brief [44] received from Amicus Curiae Pharmaceutical Research and Manufacturers of America. [540698] [CJF] [Entered: 08/03/2018 01:39 PM] (0) |
| Jul 31, 2018 | 45 | Clerk's Note to the File: Certificate of Interest for Amicus Curiae Pharmaceutical Research and Manufacturers of America is due by 08/14/2018. [539719] [CMP] [Entered: 07/31/2018 12:16 PM] (0) |
| Jul 31, 2018 | 46 | Certificate of Interest for the Amicus Curiae Pharmaceutical Research and Manufacturers of America. Service: 07/31/2018 by email. [539880] [18-1976] [Michael Kennedy] [Entered: 07/31/2018 05:09 PM] (3) |
| Jul 30, 2018 | 43 | 6 paper copies of the Amicus Brief [38] received from Amicus Curiae Biotechnology Innovation Organization. [539322] [CJF] [Entered: 07/30/2018 10:25 AM] (0) |
| Jul 27, 2018 | 40 | Notice of Correction to the Brief Doc No. [33] from Pharmaceutical Research and Manufacturers of America. Service: 07/27/2018 by email. [539028] [18-1976] [Michael Kennedy] [Entered: 07/27/2018 12:07 PM] (3) |
| Jul 27, 2018 | 41 | TENDERED from Pharmaceutical Research and Manufacturers of America Title: CORRECTED AMICUS CURIAE BRIEF. Service: 07/27/2018 by email. [539032] [18-1976] [Michael Kennedy] [Entered: 07/27/2018 12:10 PM] (20) |
| Jul 27, 2018 | 42 | Certificate of Interest for the Amicus Curiae Biotechnology Innovation Organization. Service: 07/27/2018 by email. [539121] [18-1976] [Melissa Brand] [Entered: 07/27/2018 03:25 PM] (3) |
| Jul 27, 2018 | 44 | CORRECTED AMICUS BRIEF FILED for Pharmaceutical Research and Manufacturers of America [41]. Number of Pages: 13. Service: 07/27/2018 by email. The paper copies of the brief should be received by the court on or before 08/07/2018. [539717] [CMP] [Entered: 07/31/2018 12:15 PM] (20) |
| Jul 26, 2018 | 39 | Clerk's Note to the File: Certificate of Interest for Amicus Curiae Biotechnology Innovation Organization is due by 08/09/2018. [538834] [CMP] [Entered: 07/26/2018 03:53 PM] (0) |
| Jul 23, 2018 | 29 | 6 paper copies of the Opening Brief [27] received from Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. [537649] [CJF] [Entered: 07/23/2018 10:51 AM] (0) |
| Jul 23, 2018 | 30 | Entry of appearance for Michael N. Kennedy as principal counsel for Pharmaceutical Research and Manufacturers of America (amicus). Service: 07/23/2018 by email. [537875] [18-1976] [Michael Kennedy] [Entered: 07/23/2018 03:47 PM] (2) |
| Jul 23, 2018 | 31 | Entry of appearance for David E. Korn as of counsel for Pharmaceutical Research and Manufacturers of America. Service: 07/23/2018 by email. [537883] [18-1976] [Michael Kennedy] [Entered: 07/23/2018 03:50 PM] (2) |
| Jul 23, 2018 | 32 | Entry of appearance for Steven Winkelman as of counsel for Pharmaceutical Research and Manufacturers of America. Service: 07/23/2018 by email. [537889] [18-1976] [Steven Winkelman] [Entered: 07/23/2018 03:56 PM] (2) |
| Jul 23, 2018 | 33 | TENDERED from Pharmaceutical Research and Manufacturers of America Title: AMICUS CURIAE BRIEF. Service: 07/23/2018 by email. [537947] [18-1976] This brief has been corredted. See Doc No. [44]. [Michael Kennedy] [Entered: 07/23/2018 04:29 PM] (0) |
| Jul 23, 2018 | 34 | Entry of appearance for Hans Sauer as principal counsel for Biotechnology Innovation Organization. Service: 07/23/2018 by email. [537975] [18-1976] [Melissa Brand] [Entered: 07/23/2018 05:20 PM] (2) |
| Jul 23, 2018 | 35 | Entry of appearance for Brian P. Barrett as of counsel for Biotechnology Innovation Organization. Service: 07/23/2018 by email. [537976] [18-1976] [Melissa Brand] [Entered: 07/23/2018 05:21 PM] (2) |
| Jul 23, 2018 | 36 | Entry of appearance for Melissa A. Brand as of counsel for Biotechnology Innovation Organization. Service: 07/23/2018 by email. [537977] [18-1976] [Melissa Brand] [Entered: 07/23/2018 05:25 PM] (2) |
| Jul 23, 2018 | 37 | TENDERED from Biotechnology Innovation Organization Title: AMICUS CURIAE BRIEF. Service: 07/23/2018 by email. [537978] [18-1976] [Melissa Brand] [Entered: 07/23/2018 05:27 PM] (38) |
| Jul 23, 2018 | 38 | AMICUS BRIEF FILED for Biotechnology Innovation Organization [37]. Number of Pages: 27. Service: 07/23/2018 by email. The paper copies of the brief should be received by the court on or before 08/02/2018. [538830] [CMP] [Entered: 07/26/2018 03:49 PM] (38) |
| Jul 17, 2018 | 28 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a) and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [536541] [CMP] [Entered: 07/17/2018 01:59 PM] (0) |
| Jul 16, 2018 | 26 | TENDERED from Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Title: OPENING BRIEF. Service: 07/16/2018 by email. [536234] [18-1976] [Craig Countryman] [Entered: 07/16/2018 07:26 PM] (109) |
| Jul 16, 2018 | 27 | BRIEF FILED for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited [26]. Number of Pages: 52. Service: 07/16/2018 by email. The paper copies of the brief should be received by the court on or before 07/24/2018. Cross-Appellant Teva Pharmaceuticals USA, Inc. brief is due 08/25/2018. [536535]--[Edited 07/18/2018 by SMJ to correct date] [CMP] [Entered: 07/17/2018 01:53 PM] (109) |
| May 31, 2018 | 20 | Note to file: The following cases are associated: 18-1976 Lead with 18-2023 Cross-Appeal. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [525731] [18-1976, 18-2023] [CMP] [Entered: 05/31/2018 10:07 AM] (0) |
| May 31, 2018 | 21 | Official caption revised to reflect docketing of cross-appeal. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by the Clerk of Court. [525737] [CMP] [Entered: 05/31/2018 10:16 AM] (0) |
| May 31, 2018 | 22 | Entry of appearance for Elaine Herrmann Blais as of counsel for Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 05/31/2018 by email. [526032] [18-1976] [Elaine Blais] [Entered: 05/31/2018 07:44 PM] (2) |
| May 31, 2018 | 23 | Entry of appearance for Ira J. Levy as of counsel for Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 05/31/2018 by email. [526033] [18-1976] [Ira Levy] [Entered: 05/31/2018 07:48 PM] (2) |
| May 31, 2018 | 24 | Entry of appearance for Andrew E. Riley as of counsel for Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 05/31/2018 by email. [526034] [18-1976] [Andrew Riley] [Entered: 05/31/2018 07:51 PM] (2) |
| May 31, 2018 | 25 | Entry of appearance for Lana S. Shiferman as of counsel for Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 05/31/2018 by email. [526036] [18-1976] [Lana Shiferman] [Entered: 05/31/2018 07:54 PM] (2) |
| May 30, 2018 | 2 | Entry of appearance for Craig E. Countryman as of counsel for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Service: 05/30/2018 by email. [525608] [18-1976] [Craig Countryman] [Entered: 05/30/2018 05:46 PM] (2) |
| May 30, 2018 | 3 | Entry of appearance for Michael A. Amon as of counsel for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Service: 05/30/2018 by email. [525610] [18-1976] [Craig Countryman] [Entered: 05/30/2018 05:48 PM] (2) |
| May 30, 2018 | 4 | Entry of appearance for Juanita R. Brooks as principal counsel for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Service: 05/30/2018 by email. [525614] [18-1976] [Craig Countryman] [Entered: 05/30/2018 05:50 PM] (2) |
| May 30, 2018 | 5 | Entry of appearance for William M. Jay as principal counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 05/30/2018 by email. [525615] [18-1976] [William Jay] [Entered: 05/30/2018 05:51 PM] (2) |
| May 30, 2018 | 6 | Entry of appearance for Elizabeth M. Flanagan as of counsel for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Service: 05/30/2018 by email. [525618] [18-1976] [Craig Countryman] [Entered: 05/30/2018 05:53 PM] (2) |
| May 30, 2018 | 7 | Entry of appearance for Michael J. Kane as of counsel for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Service: 05/30/2018 by email. [525622] [18-1976] [Craig Countryman] [Entered: 05/30/2018 05:54 PM] (2) |
| May 30, 2018 | 8 | Entry of appearance for Anthony J. Downs as of counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 05/30/2018 by email. [525623] [18-1976] [J. Downs] [Entered: 05/30/2018 05:55 PM] (2) |
| May 30, 2018 | 9 | Entry of appearance for Douglas E. McCann as of counsel for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Service: 05/30/2018 by email. [525625] [18-1976] [Craig Countryman] [Entered: 05/30/2018 05:55 PM] (2) |
| May 30, 2018 | 10 | Entry of appearance for Jonathan E. Singer as of counsel for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Service: 05/30/2018 by email. [525628] [18-1976] [Craig Countryman] [Entered: 05/30/2018 05:57 PM] (2) |
| May 30, 2018 | 11 | Entry of appearance for William Woodford as of counsel for Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Service: 05/30/2018 by email. [525631] [18-1976] [Craig Countryman] [Entered: 05/30/2018 05:59 PM] (2) |
| May 30, 2018 | 12 | Certificate of Interest for the Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Service: 05/30/2018 by email. [525636] [18-1976] [Craig Countryman] [Entered: 05/30/2018 06:01 PM] (3) |
| May 30, 2018 | 13 | Docketing Statement for the Appellants GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited. Service: 05/30/2018 by email. [525637] [18-1976] [Craig Countryman] [Entered: 05/30/2018 06:02 PM] (3) |
| May 30, 2018 | 14 | Entry of appearance for Christopher T. Holding as of counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 05/30/2018 by email. [525638] [18-1976] [Christopher Holding] [Entered: 05/30/2018 06:03 PM] (2) |
| May 30, 2018 | 15 | Entry of appearance for Daryl L. Wiesen as of counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 05/30/2018 by email. [525641] [18-1976] [Daryl Wiesen] [Entered: 05/30/2018 06:08 PM] (2) |
| May 30, 2018 | 16 | Entry of appearance for Robert Frederickson III as of counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 05/30/2018 by email. [525642] [18-1976] [Robert Frederickson] [Entered: 05/30/2018 06:12 PM] (2) |
| May 30, 2018 | 17 | Entry of appearance for Alexandra Lu as of counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 05/30/2018 by email. [525644] [18-1976] [Alexandra Lu] [Entered: 05/30/2018 06:16 PM] (2) |
| May 30, 2018 | 18 | Certificate of Interest for the Appellee Teva Pharmaceuticals USA, Inc.. Service: 05/30/2018 by email. [525645] [18-1976] [William Jay] [Entered: 05/30/2018 06:26 PM] (3) |
| May 30, 2018 | 19 | Docketing Statement for the Appellee Teva Pharmaceuticals USA, Inc.. Service: 05/30/2018 by email. [525646] [18-1976] [William Jay] [Entered: 05/30/2018 06:27 PM] (4) |
| May 16, 2018 | 1 | Appeal docketed. Received: 05/15/2018. [522228]Entry of Appearance due 05/30/2018. Certificate of Interest is due on 05/30/2018. Docketing Statement due 05/30/2018. Appellant's brief is due 07/16/2018. [CMP] [Entered: 05/16/2018 01:56 PM] (59) |
